You have successfully logged out.

Hello !
Logout
close

No content results match your keyword.

Content

    No product results match your keyword.

    Products

      Treatment of hydrocephalus

      MIETHKE gravitational valves

      The critical issue in shunt technology is the posture-dependent hydrostatic pressure change.

      Info graph gravitational valves improve patient outcomes compared to differential pressure valves

      Avoid complications! Avoid revisions!

      Clinical studies have shown that MIETHKE gravitational shunts reduce the risk of revisions. They exhibit a high rate of shunt survival across all age groups, with valve survival rates as high as 90% at 12 months [1] and above 80% after 2 years. [2] For infants, a group known to have a higher rate of complications than adult patients, favorable survival rates were also observed. [2] Further, the risk of overdrainage was reduced by 36% compared to conventional valves, i.e., one additional overdrainage complication in every third patient undergoing shunting can be prevented by using a gravitational valve. [5]

      Info graph avoid complications
      Info graph avoid revisions

      Prevent mechanical failure!

      All MIETHKE valves are manufactured with high precision from titanium. The strength of titanium allows the valves to be made extremely small, but with optimized flow paths. The rigid housing makes the titanium shunt valves unsusceptible to subcutaneous pressure. Titanium is considered an excellent choice for biomedical applications with high biocompatibility. [6] In addition, titanium is MRI compatibility.

      Info graph miethke gravitational valves

      Get it right the first time!

      Current evidence suggests that delay in treatment is harmful for the patient, [7] even when the delay is as short as 3 months. [8] Especially in infants with hydrocephalus, whose brains are still developing, the primary treatment choice and possible complications have a relevant impact on the long-term outcome. [9] Infants who received a gravitational shunt as part of a shunt revision had a lower rate of shunt survival than those with a primary implantation of a gravitational shunt, [9] stressing the importance of optimal primary implantation. Delay in treatment of hydrocephalus may be harmful and early intervention is indicated, particularly when considering that not all complications are reversible. Hence, it is important to make use of the best available treatment and to get it right the first time.

      Info graph benefit from primary implantation

      Optimize – don’t compromise!

      The critical issue in shunt technology is to simulate the posture-dependent hydrostatic pressure change. [10] Gravitational shunts, which compensate for posture-dependent hydrostatic pressure changes, can prevent overdrainage. [11] In the horizontal position, the gravitational valve opens completely and hence does not contribute to the overall flow resistance, while in the vertical position, the flow resistance is determined by both the gravitational valve and the differential pressure valve.

      Clinical practice has shown that the usage of programmable valves with MIETHKE gravitational shunts can lower the number of shunt revisions due to over- and underdrainage [3] and improve symptoms and the overall daily functioning. [10] Further, gravitational shunts have been shown to be efficacious in the treatment of hydrocephalus in infants. [12]

      MIETHKE gravitational shunts can compensate for overdrainage without compromising the setting for the supine position. The optimal opening pressure for each patient when standing and when lying can be set – without needing to compromise.

      Icons of lying, sitting and standing hydrocephalus patients

      Don’t let magnetic fields bother you!

      The unintentional reprogramming of valves by low-intensity magnetic fields is of great concern for patients and physicians alike. But how can one be sure that a valve will not be reprogrammed accidentally? The key question surely is whether the programmable valve is protected from reprogramming by the strong fields generated during MRI. If the magnetic fields of an MR system cannot reset the setting then low-intensity magnetic fields should also have no influence. Programmable MIETHKE valves have an ‘Active-Lock mechanism’, which protects them from reprogramming by magnetic fields of up to 3 Tesla. [13]

      Icons of mobile devices, headphones, MRI and toy magnets
      MIETHKE M.blue® gravitational valve – the next shunt generation

      The balanced way of life. Inspired by you.

      MIETHKE M.blue®

      You want to know why M.blue® is always the right decision? Learn more about how simple and individual M.blue® works and how it can facilitate your workflow. 

      Read more

      MIETHKE and B. Braun

      Together for a better life with hydrocephalus

      We have an intensive and longstanding partnership with MIETHKE in the field of neurosurgery. We are driven by a common vision: to improve the lives of hydrocephalus patients with innovative solutions.

      Read more about MIETHKE

      Related documents

      • MIETHKE Gravitational valves – designed to give you confidence

        Info graph

        pdf, 36.8 KB

      • M.blue® – shunt system for the treatment of hydrocephalus

        Patient manual

        link

      [1] Tschan CA, Antes S, Huthmann A, et al. Overcoming CSF overdrainage with the adjustable gravitational valve proSA. Acta Neurochir (Wien) 2014;156(4):767-76; discussion 76.

      [2] Sprung C, Schlosser HG, Lemcke J, et al. The adjustable proGAV shunt: a prospective safety and reliability multicenter study. Neurosurgery 2010;66(3):465-74.

      [3] Gebert AF, Schulz M, Schwarz K, Thomale UW. Long-term survival rates of gravity-assisted, adjustable differential pressure valves in infants with hydrocephalus. J Neurosurg Pediatr 2016 17:544-551

      [4] Lemcke J, Meier U, Müller C, Fritsch M, Kehler U, Langer N et al. Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA). J Neurol Neurosurg Psychiatry 2013 84(8):850-857

      [5] Thomale UW, Gebert AF, Haberl H, et al. Shunt survival rates by using the adjustable differential pressure valve combined with a gravitational unit (proGAV) in pediatric neurosurgery. Childs Nerv Syst 2013;29(3):425-31.

      [6] Lemcke J, Meier U, Muller C, et al. Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA). J Neurol Neurosurg Psychiatry 2013;84(8):850-7.

      [7] Sidambe AT. Biocompatibility of Advanced Manufactured Titanium Implants-A Review. Materials (Basel, Switzerland) 2014;7(12):8168-88.

      [8] Saini M, Singh Y, Arora O, et al. Implant biomaterials: A comprehensive review. World journal of clinical cases 2015;3(1):52-7.

      [9] Toma AK, Watkins LD. Surgical management of idiopathic normal pressure hydrocephalus: a trial of a trial. Br J Neurosurg 2016;30(6):605.

      [10] Toma AK, Stapleton S, Papadopoulos MC, et al. Natural history of idiopathic normal-pressure hydrocephalus. Neurosurg Rev 2011;34(4):433-9.

      [11] Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open 2017;7(10):e017902.

      [12] Suchorska B, Kunz M, Schniepp R, et al. Optimized surgical treatment for normal pressure hydrocephalus: comparison between gravitational and differential pressure valves. Acta Neurochir (Wien) 2015;157(4):703-9.

      [13] Chari A, Czosnyka M, Richards HK, Pickard JD, Czosnyka ZH. Hydrocephalus shunt technology: 20 years of experience from the Cambridge Shunt Evaluation Laboratory, J Neurosurg 2014;120(3): 697-707.